GDC-0449 (vismodegib)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for GDC-0449 (vismodegib), covering 2015-12-09 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery [Phase 1]